Nothing is perfect: the safety issues of integrase inhibitor regimens

References

• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Gesida: Plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana; 2019 [cited 2019 Dec 20]. Available from: http://gesida-seimc.org/category/guias-clinicas/
   Google Scholar
• AIDSinfo: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; 2019 [cited 2019 Dec 20]. Available from: https://aidsinfo.nih.gov/guidelines
   Google Scholar
• EACS: European Guidelines for the treatment of HIV-positive adults in Europe; 2019 [cited 2019 Dec 20]. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/
   Google Scholar
• Guía de resistencias a los antirretrovirales. Red de investigación en Sida. Actualización; 2019 [cited 2019 Dec 20]. Available from: https://www.redris.es/blog/-/blogs/guia-de-resistencias-a-los-antirretrovirales
   Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 Study. J Infect Dis. 2014;210:354–362.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813–821.
   PubMed Web of Science ®Google Scholar
• Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696–2705.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13:587–596.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicenter, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063–2072.
   PubMed Web of Science ®Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicenter, phase 3, noninferiority trial. Lancet. 2017;390:2073–2082.
   PubMed Web of Science ®Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22:295–305.
   PubMed Web of Science ®Google Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. Clin Pharmacokinet. 2017;56:25–40.
   PubMed Web of Science ®Google Scholar
• Lepik KJ, Yip B, Ulloa A, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018;32:903–912. DOI:10.1097/QAD.0000000000001781
   PubMed Web of Science ®Google Scholar
• Llibre JM, Montoliu A, Miró JM, et al. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Med. 2019;20:237–247. DOI:10.1111/hiv.12710
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31:1853–1858.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27:1771–1778.
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927–935.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–708.
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–2231.
   PubMed Web of Science ®Google Scholar
• Naumann U, Moll A, Schleehauf D, et al. Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2%. Int J STD AIDS. 2019;30:727–728.
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439–2448.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429–2438.
   PubMed Web of Science ®Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12:27–35.
   PubMed Web of Science ®Google Scholar
• Peñafiel J, Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72:1752–1759. DOI:10.1093/jac/dkx053
   PubMed Web of Science ®Google Scholar
• de Boer M, van den Berk G, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30:2831–2834. DOI:10.1097/QAD.0000000000001279
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Llibre JM. Neuropsychiatric Adverse Events with DTG and Other Integrase Strand Transfer Inhibitors. AIDS. 2019;21:4–10..
   Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015;70:515–519.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56–63. DOI:10.1111/hiv.12468
   PubMed Web of Science ®Google Scholar
• Cuzin L, Pugliese P, Katlama C, et al. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. J Antimicrob Chemother. 2019;74:754–760. DOI:10.1093/jac/dky497
   PubMed Web of Science ®Google Scholar
• Hsu R, Fusco J, Henegar C, et al. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Reserch and Analysis database. Ther Adv Drug Saf. 2018;9:675–686.
   PubMed Web of Science ®Google Scholar
• Orkin C, Sax PE, Arribas J, et al. Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults. 17th European AIDS Conference; Basel; 2019 November. Abstract PE3/14.
   Google Scholar
• Hoffmann C, Schewe K, Fenske S, et al. Neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice. 17th European AIDS Conference; Basel; 2019 November. Abstract PE2/25
   Google Scholar
• Wohl D, Clarke A, Maggiolo F, et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018;11:561–573.
   PubMedGoogle Scholar
• Zash R, Makhema J, Shapiro RL, et al. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379:979–981. DOI:10.1056/NEJMc1807653
   PubMed Web of Science ®Google Scholar
• Shamsuddin H, Raudenbush CL, Sciba BL, et al. Evaluation of neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy. J Acquir Immune Defic Syndr. 2019;81:247–250.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Dec 20]. Available from: https://www.who.int/hiv/mediacentre/news/dtg-statement/en/
   Google Scholar
• Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381:827–840. DOI:10.1056/NEJMoa1905230
   PubMed Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M, et al. Dolutegravir Use at Conception – additional Surveillance Data from Botswana. N Engl J Med. 2019;381:885–887.
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Vannappagari V, Scheuerle AE, et al. Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR). 17th European AIDS Conference; 2019 November 69; Basel, Switzerland.
   Google Scholar
• Pereira G, Kim A, Jalil E, et al. No ocurrence of NTD among 382 women on dolutegravir at pregnancy conception in Brazil. IAS; 2019 . [cited 2019 Dec 20]. Available from: http://programme.ias2019.org/Abrstract/4991.
   Google Scholar
• Blencowe H, Kancherla V, Moorthie S, et al. Estimates of global and regional prevalences of neural tube defects for 2015: a systematic analysis. Ann NY Acad Sci. 2018;1414:31–46.
   PubMed Web of Science ®Google Scholar
• AIDSinfo: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States; 2019 [cited 2019 Dec 26]. Available from: https://aidsinfo.nih.gov/guidelines
   Google Scholar
• Orkin C, Ajana F, Kityo C, et al. Efficacy and safety of bictegravir/emitricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials. 17th European AIDS Conference; 2019 November 69; Basel. Abstract PS7/6
   Google Scholar
• Gorwood J, Bourgeois C, Pourcher V, et al. Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes. 17th European AIDS Conference; 2019 Nov 6–9, Basel, Switzerland. abstract PS3/4.
   Google Scholar
• European Medicines Agency. EMA/CHMP/772068/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report. Tivicay. International non-proprietary name: dolutegravir Procedure No. EMEA/H/C/002753/0000. 2013 November 21. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay
   Google Scholar
• Kouanfack C, Mpoudi-Etame M, Bassega P, et al. Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381:816–826.
   PubMed Web of Science ®Google Scholar
• Venter W, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381:803–815. DOI:10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• McCann K, Moorhouse M, Sokhela S, et al. The ADVANCE clinical trial: changes from baseline to week 96 in DXA‐assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV. 17th European AIDS Conference, abstract PS3/3; 2019; Basel.
   Google Scholar
• Hare CB, Coll J, Ruane P, et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Conference on Retroviruses and Opportunistic Infections; 2019 March 4–7; Seattle, Washington. Abstract 104LB.
   Google Scholar
• Rebeiro P, Jenkins C, Bian A, et al. The effect of initiating integrase inhibitor-based vs non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy on progression to diabetes among North American persons in HIV care. IDWeek, abstract LB9; 2019; Washington, DC.
   Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019:pii: ciz999. DOI: 10.1093/cid/ciz999.
   Web of Science ®Google Scholar
• Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;8(15):e1002690. DOI:10.1371/journal.pmed.1002690.
   Google Scholar
• Murray MI, Markowitz M, Frank I. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018;19:129–138.
   PubMed Web of Science ®Google Scholar
• Murray M, Pulido F, Mills A, et al. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019;20:111–122. DOI:10.1080/25787489.2019.1661696
   PubMedGoogle Scholar
• Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long acting Cabotegravir + Rilpivirine for HIV maintenance: ATLAS week 48 results. CROI; 2019; Seattle. Abstract 139.
   Google Scholar
• Orkin C, Arastéh K, Hernandez-Mora Gorgolas M, et al. Llong acting Cabotegravir + Rilpivirine for HIV maintenance: FLAIR week 48 results. CROI; 2019; Seattle. Abstract 140.
   Google Scholar
• Margolis D, Sutton K, De Vente J, et al. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results. Presentation 2840. ID-Week. 2019 Oct 2–6; Washington, DC.
   Google Scholar
• Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in HIV-uninfected individuals in HPTN 077. Clin Infect Dis Brief Rep. 2020 Jan 15;70(2):319–322. DOI:10.1093/cid/ciz439.
   Web of Science ®Google Scholar
• Perry ME, Almaani N, Desai N, et al. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety. Int J STD AIDS. 2013;24:639–642.
   PubMed Web of Science ®Google Scholar
• Yee BE, Nguyen NH, Lee D. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV. BMJ Case Rep. 2014;2014:pii: bcr2013201545.
   PubMedGoogle Scholar
• Ripamonti D, Benatti SV, Di Filippo E, et al. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. AIDS. 2014;28:1077–1079.
   Google Scholar
• Brandariz D, Smithson A, Anton-Vazquez V. Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients. Indian J Sex Transm Dis AIDS. 2017;38:163–170.
   PubMed Web of Science ®Google Scholar
• Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? Int J STD AIDS. 2018;29:1036–1038.
   PubMed Web of Science ®Google Scholar
• Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45:289–294.
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Pich J, et al. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013;68:404–408.
   PubMed Web of Science ®Google Scholar
• Calza L, Danese I, Colangeli V, et al. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. AIDS Res Hum Retroviruses. 2014;30:1162–1169.
   PubMed Web of Science ®Google Scholar
• Chen GJ, Sun HY, Cheng A, et al. Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir based combination antiretroviral therapy. Medicine (Baltimore). 2019;98:26 (e16235).
   Web of Science ®Google Scholar
• Godinho R, Bugnon S, Gracin T, et al. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report. BMC Nephrol. 2019;20:69.
   PubMed Web of Science ®Google Scholar
• Suttels V, Florence E, Leys J, et al. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. J Med Case Rep. 2015;9:190.
   PubMedGoogle Scholar
• Sax PE, De Jesus E, Crofoot G, et al. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 2018;32:1723–1725.
   PubMed Web of Science ®Google Scholar